These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 9335087)
21. Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals. Cho R; Kapur S; Du L; Hrdina P Neurosci Lett; 1999 Feb; 261(3):139-42. PubMed ID: 10081968 [TBL] [Abstract][Full Text] [Related]
25. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Meyer JH; Kapur S; Houle S; DaSilva J; Owczarek B; Brown GM; Wilson AA; Kennedy SH Am J Psychiatry; 1999 Jul; 156(7):1029-34. PubMed ID: 10401447 [TBL] [Abstract][Full Text] [Related]
26. Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126 [TBL] [Abstract][Full Text] [Related]
27. 5-HT2A: its role in frontally mediated executive function and related psychopathology. Stein DJ; Hemmings S; Moolman-Smook H; Audenaert K CNS Spectr; 2007 Jul; 12(7):512-6. PubMed ID: 17603401 [TBL] [Abstract][Full Text] [Related]
29. Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors. Lucini V; Lucca A; Catalano M; Smeraldi E Adv Exp Med Biol; 1996; 398():559. PubMed ID: 8906324 [No Abstract] [Full Text] [Related]
30. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399 [TBL] [Abstract][Full Text] [Related]
31. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Hatanaka K; Nomura T; Hidaka K; Takeuchi H; Yatsugi S; Fujii M; Yamaguchi T Neuropharmacology; 1996; 35(11):1621-6. PubMed ID: 9025110 [TBL] [Abstract][Full Text] [Related]
32. Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. Smith GS; Price JC; Lopresti BJ; Huang Y; Simpson N; Holt D; Mason NS; Meltzer CC; Sweet RA; Nichols T; Sashin D; Mathis CA Synapse; 1998 Dec; 30(4):380-92. PubMed ID: 9826230 [TBL] [Abstract][Full Text] [Related]
33. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Baumann P Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S35-43. PubMed ID: 9817619 [TBL] [Abstract][Full Text] [Related]
34. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. Zanardi R; Artigas F; Moresco R; Colombo C; Messa C; Gobbo C; Smeraldi E; Fazio F J Clin Psychopharmacol; 2001 Feb; 21(1):53-8. PubMed ID: 11199948 [TBL] [Abstract][Full Text] [Related]
35. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Verhoeff NP; Meyer JH; Kecojevic A; Hussey D; Lewis R; Tauscher J; Zipursky RB; Kapur S Psychiatry Res; 2000 Oct; 99(3):123-35. PubMed ID: 11068194 [TBL] [Abstract][Full Text] [Related]
37. Serotonergic mechanisms and the new antidepressants. Stahl SM Psychol Med; 1993 May; 23(2):281-5. PubMed ID: 8332642 [No Abstract] [Full Text] [Related]
38. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Yamauchi M; Miyara T; Matsushima T; Imanishi T Brain Res; 2006 Jan; 1067(1):164-9. PubMed ID: 16360124 [TBL] [Abstract][Full Text] [Related]
39. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Trichard C; Paillère-Martinot ML; Attar-Levy D; Blin J; Feline A; Martinot JL Schizophr Res; 1998 May; 31(1):13-7. PubMed ID: 9633832 [TBL] [Abstract][Full Text] [Related]
40. The potential benefit of combined versus monotherapy of coenzyme Q10 and fluoxetine on depressive-like behaviors and intermediates coupled to Gsk-3β in rats. Abuelezz SA; Hendawy N; Magdy Y Toxicol Appl Pharmacol; 2018 Feb; 340():39-48. PubMed ID: 29291430 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]